Related Experiment Video
Updated: Aug 1, 2025

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
PET Imaging in Bladder Cancer: An Update and Future Direction
Jules Zhang-Yin1, Antoine Girard2, Etienne Marchal2
1Department of Nuclear Medicine, Clinique Sud Luxembourg, Vivalia, B-6700 Arlon, Belgium.
Abstract:
Molecular imaging with positron emission tomography is a powerful tool in bladder cancer management. In this review, we aim to address the current place of the PET imaging in bladder cancer care and offer perspectives on potential future radiopharmaceutical and technological advancements. A special focus is given to the following: the role of [18F] 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in the clinical management of bladder cancer patients, especially for staging and follow-up; treatment guided by [18F]FDG PET/CT; the role of [18F]FDG PET/MRI, the other PET radiopharmaceuticals beyond [18F]FDG, such as [68Ga]- or [18F]-labeled fibroblast activation protein inhibitor; and the application of artificial intelligence.
Related Concept Videos
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Imaging Studies II: Ultrasonography
Imaging Studies III: Computed Tomography
Imaging Studies VI: Voiding Cystourethrography and Cystography
Imaging Studies IV: Magnetic Resonance Imaging
Imaging Studies I: Kidney, Ureter, and Bladder Studies

